We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2.32B
1-Year Est. Return 536.01%
This Fund
S&P 500
This Quarter Est. Return
+40.06%
1 Year Est. Return
+536.01%
3 Year Est. Return
+1,584.92%
5 Year Est. Return
+2,855.24%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
+$164M
Cap. Flow
-$43.3M
Cap. Flow %
-3.5%
Top 10 Hldgs %
53.52%
Holding
82
New
29
Increased
10
Reduced
10
Closed
25

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$49M
2
IMCR icon
Immunocore
IMCR
+$34.3M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.7M
4
SLN
Silence Therapeutics
SLN
+$23.4M
5
ADVM
Adverum Biotechnologies
ADVM
+$22.8M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$118M
2
ARGX icon
argenx
ARGX
+$55.2M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$35.3M
4
AMAM
Ambrx Biopharma Inc
AMAM
+$29.9M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 76.89%
2 Miscellaneous 23.1%
3 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
CALL
DELISTED
Astria Therapeutics
ATXS
$14.1M 1.14%
+1,000,000
New +$12.5M
CGON icon
27
CG Oncology
CGON
$6.7B
$13.2M 1.07%
+300,000
New +$12.3M
ENGN icon
28
enGene Therapeutics
ENGN
$128M
$12.9M 1.04%
+800,000
New +$9.79M
KYTX icon
29
Kyverna Therapeutics
KYTX
$435M
$12.4M 1.01%
+500,000
New +$14M
VRDN icon
30
Viridian Therapeutics
VRDN
$2.48B
$12.3M 0.99%
700,000
+100,000
+17% +$1.94M
CGEM icon
31
Cullinan Oncology
CGEM
$1.37B
$11.9M 0.97%
+700,000
New +$10.8M
IMTX icon
32
Immatics
IMTX
$1.34B
$10.5M 0.85%
+1,000,000
New +$11.7M
SYRE icon
33
Spyre Therapeutics
SYRE
$8.17B
$9.48M 0.77%
250,000
+100,000
+67% +$2.9M
FULC icon
34
CALL
Fulcrum Therapeutics
FULC
$288M
$9.44M 0.76%
+1,000,000
New +$8.93M
LCTX icon
35
Lineage Cell Therapeutics
LCTX
$260M
$9.25M 0.75%
+6,250,000
New +$7.09M
PRAX icon
36
Praxis Precision Medicines
PRAX
$8.67B
$9.15M 0.74%
+150,000
New +$6.73M
APLT
37
DELISTED
Applied Therapeutics
APLT
$8.98M 0.73%
1,350,000
-310,000
-19% -$1.39M
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.58B
$8.33M 0.67%
+350,000
New +$7.81M
TRVI icon
39
Trevi Therapeutics
TRVI
$2.17B
$7.59M 0.61%
+2,200,000
New +$4.91M
ANNX icon
40
CALL
Annexon
ANNX
$791M
$7.17M 0.58%
+1,000,000
New +$5.19M
CYTK icon
41
Cytokinetics
CYTK
$9.72B
$7.01M 0.57%
100,000
-1,525,000
-94% -$118M
KURA icon
42
Kura Oncology
KURA
$1.04B
$6.4M 0.52%
+300,000
New +$5.83M
NMRA icon
43
Neumora Therapeutics
NMRA
$141M
$6.19M 0.5%
382,345
– –
ATYR
44
aTyr Pharma
ATYR
$36.9M
$6.04M 0.49%
3,100,000
-2,750,000
-47% -$4.8M
JANX icon
45
Janux Therapeutics
JANX
$1.03B
$5.65M 0.46%
+150,000
New +$3.27M
LRMR icon
46
CALL
Larimar Therapeutics
LRMR
$395M
$5.31M 0.43%
+700,000
New +$5.45M
ELEV
47
DELISTED
Elevation Oncology
ELEV
$5.13M 0.42%
+1,000,000
New +$3.24M
NXTC icon
48
NextCure
NXTC
$26M
$4.29M 0.35%
+160,417
New +$2.76M
ALLK
49
DELISTED
Allakos
ALLK
$3.65M 0.3%
2,900,000
– –
UNCY icon
50
Unicycive Therapeutics
UNCY
$133M
$3.01M 0.24%
+346,993
New +$4.21M
1
2
3 4

Similar funds

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
CWM
Cornerstone Wealth Management St. Peters, Missouri $2.33B AUM 25.21% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
NP
NS Partners London, United Kingdom $2.33B AUM 35.18% 1-Year Est. Return
AI
Accredited Investors Edina, Minnesota $2.31B AUM 33.7% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $2.31B AUM 18.36% 1-Year Est. Return
HHGA
Halbert Hargrove Global Advisors Long Beach, California $2.31B AUM 21.64% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $2.31B AUM 26.52% 1-Year Est. Return

Logos Global Management's Q1 2024 Portfolio in Review

As of Q1 2024, Logos Global Management held 82 positions worth $1.24B, up 15% from $1.07B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Logos Global Management withdrew a net $43.3M in Q1 2024, closing 25 positions and reducing 10 holdings. Its most notable exit was argenx, an estimated $55.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Logos Global Management opened a new position in Sarepta Therapeutics worth $51.8M.

  • Logos Global Management's largest Q1 2024 buy was Sarepta Therapeutics: 400,000 shares worth $51.8M.
  • Logos Global Management added most to Immunocore in Q1 2024, an estimated $34.3M increase.
  • Logos Global Management's biggest Q1 2024 reduction was Cytokinetics, cutting an estimated $118M.
  • Logos Global Management fully exited argenx in Q1 2024, selling an estimated $55.2M.
  • Logos Global Management's ten largest holdings make up 54% of its $1.24B portfolio in Q1 2024.
  • Logos Global Management opened 29 new positions and closed 25 in Q1 2024.
  • Logos Global Management's portfolio value rose 15% quarter-over-quarter to $1.24B.

Based on Logos Global Management's 13F filing for Q1 2024, filed 15 May 2024.